Wang 2007.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: outpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). BPRS of 35 or more. N = 95. Age: aripiprazole group: 16～54 years. mean = (24.4 ± 13.2) years; risperidone group: 13～67 years, mean = (25. 4 ± 14. 6) years. Gender: aripiprazole group: 22 male, 24 female; risperidone group: 23 male, 26 female. History: not reported. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐30 mg/day. Mean dose: not reported. N = 46. 2. Risperidone: Dose range: 1‐6 mg/day. Mean dose: not reported. N = 49.
Outcomes	Global state: PANSS score decreased rate (recovery: ≥ 75%, markedly improved: 50%‐75%, improved: 25%‐50%, no effect: < 25%). Mental state: PANSS total score. Leaving the study early. Adverse effects. Unable to use ‐ Adverse effects: TESS total score, blood routine, use of benzodiazepines and anticholinergic medication (no data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Total proportion of drop‐out was 3.15% and the data of the two groups were balanced (2/46: 1/49). Two because of adverse effect, one due to economic issue.
Selective reporting (reporting bias)	High risk	Data on TESS total score, blood routine, use of benzodiazepines and anticholinergic medication were missing.
Other bias	Low risk	None obvious.